Influence of luminal and basal subtype in prognosis of high-grade non muscle invasive urothelial carcinoma.

[1]  J. Sfakianos,et al.  Tumor Heterogeneity and Consequences for Bladder Cancer Treatment , 2021, Cancers.

[2]  D. Mukherji,et al.  Triple‐marker immunohistochemical assessment of muscle‐invasive bladder cancer: Is there prognostic significance? , 2021, Cancer reports.

[3]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[4]  A. Basiri,et al.  Association of immunohistochemical markers of tumor subtype with response to neoadjuvant chemotherapy and survival in patients with muscle-invasive bladder cancer , 2020, Investigative and clinical urology.

[5]  J. Weinstein,et al.  Assessment of Luminal and Basal Phenotypes in Bladder Cancer , 2020, Scientific Reports.

[6]  K. Moon,et al.  CK14 Expression Identifies a Basal/Squamous-Like Type of Papillary Non-Muscle-Invasive Upper Tract Urothelial Carcinoma , 2020, Frontiers in Oncology.

[7]  K. Moon,et al.  Clinical outcomes of muscle invasive bladder Cancer according to the BASQ classification , 2019, BMC Cancer.

[8]  E. Plimack,et al.  Clinical implications of molecular subtyping in bladder cancer. , 2019, Current opinion in urology.

[9]  A. Lopez‐Beltran,et al.  Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype , 2019, Virchows Archiv.

[10]  F. Sanguedolce,et al.  Diagnostic and prognostic roles of CK20 in the pathology of urothelial lesions. A systematic review. , 2019, Pathology, research and practice.

[11]  K. Moon,et al.  Immunohistochemistry of cytokeratin (CK) 5/6, CD44 and CK20 as prognostic biomarkers of non‐muscle‐invasive papillary upper tract urothelial carcinoma , 2018, Histopathology.

[12]  J. Raman,et al.  Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants. , 2019, European urology.

[13]  Steven J. M. Jones,et al.  Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer , 2017, Cell.

[14]  M. Höglund,et al.  Molecular classification of urothelial carcinoma: global mRNA classification versus tumour‐cell phenotype classification , 2017, The Journal of pathology.

[15]  Jacques Ferlay,et al.  Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. , 2017, European urology.

[16]  J. Weinstein,et al.  Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use , 2016, EBioMedicine.

[17]  Y. Lotan,et al.  Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes. , 2016, European urology.

[18]  M. Höglund,et al.  Biological determinants of bladder cancer gene expression subtypes , 2015, Scientific Reports.

[19]  S. Minner,et al.  Gender-specific outcomes of bladder cancer patients: a stage-specific analysis in a contemporary, homogenous radical cystectomy cohort. , 2015, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[20]  A. Masson-Lecomte,et al.  Gender-specific differences in clinicopathologic outcomes following radical cystectomy: an international multi-institutional study of more than 8000 patients. , 2014, European urology.

[21]  Y. Lotan,et al.  The economics of bladder cancer: costs and considerations of caring for this disease. , 2014, European urology.

[22]  Xiaoping Su,et al.  Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer , 2014, Nature Reviews Urology.

[23]  Katherine A. Hoadley,et al.  Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology , 2014, Proceedings of the National Academy of Sciences.

[24]  K. Baggerly,et al.  Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. , 2014, Cancer cell.

[25]  The Cancer Genome Atlas Research Network,et al.  Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.

[26]  S. Dalal,et al.  Novel function of keratins 5 and 14 in proliferation and differentiation of stratified epithelial cells , 2011, Molecular biology of the cell.

[27]  G. Blobel,et al.  GATA Transcription Factors and Cancer. , 2010, Genes & cancer.

[28]  Z. Werb,et al.  GATA3 in development and cancer differentiation: Cells GATA have it! , 2010, Journal of cellular physiology.

[29]  Robert J. Marinelli,et al.  Placental S100 (S100P) and GATA3: Markers for Transitional Epithelium and Urothelial Carcinoma Discovered by Complementary DNA Microarray , 2007, The American journal of surgical pathology.

[30]  L. Kiemeney,et al.  Epidemiology of Bladder Cancer , 1999, European Urology.